Last update 28 Sep 2024

Golidocitinib

Last update 28 Sep 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(R)-N-(3-(2-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propenamide hemi ethyl acetate solvate, Golidocitnib, AZD-4205

+ [5]

Target

JAK1

Mechanism

JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [3]

Active Indication

Peripheral T-Cell LymphomaNon-Small Cell Lung CancerT-cell lymphoma recurrent+ [2]

Inactive Indication

EGFR-mutated non-small Cell Lung Cancer

Originator Organization

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

AstraZeneca PLC

Active Organization

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Inactive Organization

AstraZeneca PLC

Drug Highest PhaseApproved

First Approval Date

CN (18 Jun 2024),

Peripheral T-Cell Lymphoma

RegulationFast Track (US), Orphan Drug (US), Priority Review (CN), Conditional marketing approval (CN)

Structure

Molecular FormulaC25H31N9O2

InChIKeyCVCVOSPZEVINRM-MRXNPFEDSA-N

CAS Registry2091134-68-6

Clinical Trials associated with Golidocitinib

NCT06573138 / Not yet recruitingPhase 2IIT

The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma

A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.

Start Date01 Sep 2024

Sponsor / Collaborator

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

NCT06198907 / Not yet recruitingPhase 2IIT

A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)

Start Date01 Jan 2024

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

[+1]

NCT05963347 / RecruitingPhase 2IIT

A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL)

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).

Start Date03 Aug 2023

Sponsor / Collaborator

Henan Cancer Hospital

100 Clinical Results associated with Golidocitinib

100 Translational Medicine associated with Golidocitinib

100 Patents (Medical) associated with Golidocitinib

Literatures (Medical) associated with Golidocitinib

01 Oct 2024·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Pd(II) coordination molecule modified g-C3N4 for boosting photocatalytic hydrogen production

Article

Author: Zhou, Xiaoqin ; Yu, Xiaoxing ; Luo, Jin ; Ning, Xiaomei ; Zhou, Xunfu ; Fan, Xuliang ; Peng, Lanzhen ; Zhou, Xiaosong

The photocatalytic H₂ production activity of polymer carbon nitride (g-C₃N₄) is limited by the rapid recombination of photoelectron-hole pairs and slow surface reduction dynamic process. Here, a supramolecular complex (named R-TAP-Pd(II)) was fabricated via self-assembly of (R)-N-(1-phenylethyl)-4-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)benzamide (R-TAP) with Pd(II) and used to modify g-C₃N₄. In the R-TAP-Pd(II)@g-C₃N₄ composite photocatalyst, the spin polarization of R-TAP-Pd(II) can promote charge transfer and inhibit photogenerated carrier recombination, as confirmed by spectral tests and photoelectrochemical performance tests. Electrochemical tests and in situ X-ray photoelectron spectroscopy (XPS) tests proved that the Pd(II) ion in the R-TAP-Pd(II) molecule can serve as active sites to accelerate H₂ production. The R-TAP-Pd(II)@g-C₃N₄ presented a photocatalytic H₂ generation rate of 1085 μmol g^-1 h^-1 when exposed to visible light, which was a about 278-fold increase compared with g-C₃N₄. This work finds a new approach to boost the photocatalytic efficiency of g-C₃N₄ via supramolecular self-assembly.

19 Sep 2024·DRUGS

Golidocitinib: First Approval.

Review

Author: Keam, Susan J

Golidocitinib (^®) is an oral, potent, selective Janus kinase 1 (JAK1) inhibitor being developed by Dizal (Jiangsu) Pharmaceutical Co., Ltd for the treatment of cancer, including peripheral T cell lymphoma (PTCL). In June 2024, golidocitinib received conditional approval in China for the treatment of adult patients with relapsed or refractory (r/r) PTCL who have received at least one line of systemic treatment. This article summarizes the milestones in the development of golidocitinib leading to this first approval for the treatment of adults with PTCL.

15 Apr 2024·Cancer

Golidocitinib favorable for relapsed/refractory T‐cell lymphoma

Author: Nierengarten, Mary Beth

Dolidocitinib, an oral selective JAK1 tyrosine kinase inhibitor, shows promising antitumor activity in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL) and warrants further study in randomized clin. trials to confirm its activity and efficacy in this setting, report investigators in a phase 2, open-label study published in Lancet Oncol.Among 88 heavily pretreated patients with relapsed/ refractory PTCL treated with golidocitinib, 44% achieved an objective response rate (ORR) and 24% a complete response rate (CRR) (per an independent review committee), at a median follow-up of 13.3 mo.All patients received oral golidocitinib (150 mg once daily) until experiencing disease progression or meeting other discontinuation criteria.Sixty-one of the 104 patients included in the safety anal. (59%) had grade 3-4 drug-related adverse events, which included decreases in neutrophil (29%), white blood cell (26%), lymphocyte (21%), and platelet counts (20%).All these events were clin. manageable and reversible according to the investigators.Serious treatment-related adverse events occurred in 24% of the patients, and three patients died (two of pneumonia and one of a confusional state).Results that the ORR and CRR with golidocitinib were in line with the efficacy preliminarily observed with other new agents in an advanced stage of development in this setting, namely duvelisib and valemetostat.The preliminary data on those agents showing an ORR of approx. 50% and a CRR of approx. 30%-35% are confirmed, all three agents will be well positioned to move the field forward and be competitive for regulatory approval, adding much needed options to the treatment landscape for PTCL.Similarly to other phase 2 trials in this setting, however, he notes that the study lacked patients with rare subtypes such as monomorphic epitheliotropic intestinal T-cell lymphoma and hepatosplenic T-cell lymphoma.

News (Medical) associated with Golidocitinib

26 Jun 2024

·www.fiercepharma.com

Despite J&J's Rybrevant full nod, FDA encourages Dizal to file rival lung cancer drug for accelerated approval

The FDA confirmed the accelerated approval pathway for Dizal's sunvozertinib in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations The FDA in March converted Johnson & Johnson’s Rybrevant use in previously treated EGFR exon20 insertion-mutated non-small cell lung cancer into a full nod. But the door to an accelerated approval in the same indication remains open, according to Dizal Pharma. “The FDA actually encouraged us […] to submit as soon as possible,” Dizal CEO Xiaolin Zhang, Ph.D., told Fierce Pharma on the sidelines of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago early June. Dizal is developing the EGFR tyrosine kinase inhibitor sunvozertinib, which was approved in China in August for pretreated NSCLC with EGFR exon 20 insertion mutations. After a positive global pivotal trial readout and what Zhang described as a successful pre-NDA meeting with the FDA, the AstraZeneca spinout is on the verge of filing for an accelerated approval in the U.S. The FDA confirmed the accelerated approval pathway and then granted breakthrough therapy designation to sunvozertinib as a frontline treatment after the agency had handed J&J’s Rybrevant its full nod, which came hand-in-hand with a first-line approval. “Clearly, the FDA views there are patients’ needs for alternative or better therapies for this disease,” Zhang said. The FDA has in the past turned away accelerated approval applications when a full approval was already in place. Back in 2021, Agenus was forced to pull a cervical cancer submission for balstilimab after the FDA granted full approval to Merck’s Keytruda in the same indication. While both balstilimab and Keytruda are PD-1 inhibitors, sunvozertinib and Rybrevant are different, as the J&J drug is an EGFR-MET bispecific antibody. With an FDA filing around the corner, Dizal has been in discussion with multiple larger pharma companies to team up on sunvozertinib, Zhang said. Many potential partners were waiting for results from the global WU-KONG1B trial presented at ASCO 2024 and were asking questions about the first-line setting, where the drug’s key opportunity lies. Dizal is open to all deal types, Zhang said. As to whether the biotech can take U.S. commercialization in its own hands, the CEO said he’s comfortable with the company’s cash flow, especially now that sunvozertinib has started generating revenue. “We’re going to do the best deal that maximizes that potential of sunvozertinib commercially and benefit our patients,” Zhang said. “We are not going to do a deal for the sake of it.” Sunvozertinib has proven its worth in the single-arm, pivotal WU-KONG1B trial, which enrolled more than 40% non-Asian patients. As of a data cut in March, investigators recorded a best overall response rate (ORR) of 53.3% and a confirmed ORR of 44.9%, including two confirmed complete responses, among 107 patients who received sunvozertinib at the recommended 300mg dose. Notably, the drug showed anti-tumor effect regardless of prior treatment with Rybrevant. The best ORRs for those with or without prior exposure to the J&J drug were similar at 50% and 53.8%, respectively. The median duration of response was not reached, and 57% of patients were in remission for at least nine months. Dizal can’t file just yet because the FDA wants at least six-month follow-up for the last responder. And Dizal could have that additional data late June, Zhang said. When Rybrevant got its accelerated approval in 2021, the drug’s ORR was 40% with a median response duration of 11.1 months. Sunvozertinib’s tumor shrinkage data also appeared to be far better than Takeda’s disgraced small-molecule drug Exkivity, which got a conditional nod based on a 28% ORR. Takeda has decided to pull Exkivity off the market after failing a confirmatory phase 3 trial in the first-line setting. Dizal designed sunvozertinib in a flexible way to accommodate different types of EGFR exon 20 insertions, as well as some potency against wild-type EGFR, Zhang explained. Other drugs that focus on certain more sensitive insertions may have strong inhibition in those subtypes but may be too weak elsewhere. To shoot for an accelerated approval, the FDA has been requiring that a confirmatory trial be underway. The phase 3 WU-KONG28 trial could serve that purpose, and it’s already 70% enrolled, according to Zhang. The study is evaluating sunvozertinib monotherapy versus platinum-based doublet chemotherapy in first-line EGFR exon 20-mutated NSCLC. J&J’s Rybrevant succeeded in the first line as part of a combination with chemotherapy, while Takeda’s Exkivity flopped as a monotherapy. Still, Zhang believes single-agent sunvozertinib is the right approach because in newly diagnosed patients, quality of life is important. “Our view is that in the first line, the goal of treatment is different from later lines,” Zhang explained. “You want to keep the [progression-free survival] as long as you can, and the patient sill have very good quality of life because these are patients who generally have a reasonable daily life. So, we don’t think, if possible, that first-line combo with chemo is a desirable strategy. Once you have chemo, then that patient’s quality [of life] immediately goes down.” At last year’s European Society of Medical Oncology annual meeting, Dizal unveiled a pooled analysis of early-phase data for sunvozertinib monotherapy in first-line EGFR exon 20 NSCLC, showing a median progression-free survival of 12.4 months. The result compared favorable to Rybrevant-plus-chemo’s 11.4 months from J&J’s phase 3 PAPILLON trial. J&J is also angling Rybrevant for the more common EGFR mutations involving exon 19 and exon 21, which is currently dominated by AstraZeneca’s Tagrisso. Zhang, who previously led AZ’s China innovation center before its spinoff into Dizal, knows Tagrisso very well. Tagrisso has established itself very well in common EGFR mutations, Zhang said, “so we focus on second-line treatment after Tagrisso failure.” And that’s where Dizal will explore combinations with sunvozertinib. These include pairings with chemotherapy and with Dizal’s JAK1 inhibitor golidocitinib, which last week won Chinese approval for peripheral T-cell lymphoma. And the company has DZD6008, an EGFR inhibitor specifically designed for post-Tagrisso treatment.

Phase 3Clinical ResultDrug ApprovalBreakthrough TherapyASCO

20 Jun 2024

·www.pharmaceutical-technology.com

China NMPA approves Dizal’s golidocitinib for PTCL treatment

PTCL represents a diverse group of aggressive non-Hodgkin lymphomas, with patients at a high risk of disease relapse. Credit: Nemes Laszlo / Shutterstock. The National Medical Products Administration (NMPA) of China has approved Dizal’s golidocitinib for adults with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL). This is the first global approval of a Janus kinase 1 (JAK1) selective inhibitor for r/r PTCL patients whose disease has advanced following a minimum of one previous systemic therapy or who were refractory to this. PTCL represents a diverse group of aggressive non-Hodgkin lymphomas, with patients at a high risk of disease relapse. The approval is based on the data from the multinational JACKPOT8 Part B study to assess the safety and efficacy of golidocitinib monotherapy in r/r PTCL patients. Objective response rate (ORR) was the trial’s primary endpoint. See Also: SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval Golidocitinib offered superior and lasting antitumor efficacy and had a favourable safety profile versus current treatments. The ORR was 44.3% with a complete response rate of 23.9%, according to an independent review committee. Patients across a range of PTCL subtypes experienced tumour responses, with a median duration of response of 20.7 months. Notably, 53.8% of patients were still responding at the time of the analysis. Dizal CEO Xiaolin Zhang said: “We are thrilled to bring golidocitinib, the world’s first JAK1-only inhibitor, to patients in China, marking the second approved innovative drug from Dizal. “Golidocitinib yields good antitumour efficacy across different subtypes of PTCL, which differentiate golidocitinib from other targeted therapies. At Dizal, we aspire to discover and develop first-in-class and groundbreaking new medicines to address unmet medical needs around the world. With the US FDA fast track designation, we are expediting global development of golidocitinib to bring this exciting drug to patients worldwide.”

Fast TrackDrug ApprovalClinical Result

19 Jun 2024

·www.prnewswire.com

Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/r PTCL patients, compared with existing treatment options. SHANGHAI, June 19, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, today announced that the National Medical Products Administration of China has approved golidocitinib for the treatment of adult patients with relapsed or refractory (r/r) peripheral T-Cell lymphoma (PTCL) whose disease has progressed on or were refractory to at least 1 prior systemic therapy. To date, golidocitinib is the first and only approved Janus kinase 1 (JAK1) selective inhibitor for r/r PTCL patients globally. PTCL is a heterogeneous group of aggressive T-cell/natural killer (NK) cell non-Hodgkin lymphomas (NHL). Patients with PTCL face an extremely high risk of disease relapse even if they achieved tumor remission following first-line conventional therapy. The outcome for relapsed or refractory patients is extremely poor, with a 3-year survival rate of 23% and a median overall survival (mos.) of 5.8 months. Although couple of drugs have been granted conditional approval by regulatory agencies in the relapsed or refractory setting, their single agent activities have been modest, with objective response rates (ORRs) lower than 30%. Golidocitinib was approved based on findings from JACKPOT8 Part B (JACKPOT8B) study, the multinational pivotal study to evaluate the efficacy and safety of golidocitinib in r/r PTCL as a monotherapy. The primary endpoint was the objective response rate (ORR), assessed by an independent review committee (IRC). Full analysis of the study was simultaneously published in The Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting and Exposition. In JACKPOT8B study, golidocitinib demonstrated superior and durable antitumor efficacy and a favorable safety profile in r/r PTCL patients, compared with existing treatment options. At the data cut-off date August 31, 2023, the ORR was 44.3% including a complete response (CR) rate of 23.9% per IRC. Tumor responses were observed across various PTCL subtypes. The median duration of response (mDoR) was 20.7 months and 53.8% of patients were still responding. "Golidocitinib features novel mechanism and unique molecular design, positioning it as the first oral JAK1 only inhibitor for the treatment of r/r PTCL. Multiple studies have clearly demonstrated its favorable pharmacokinetic properties and significant clinical benefit," said Jun Zhu, MD, PhD at the Department of Lymphoma, Peking University Cancer Hospital and Institute, the leading principal investigator of the JACKPOT8B study, "Golidocitinib achieved an ORR of 44.3% and a DoR of 20.7 months in r/r PTCL. It's approval and market launch provide a much needed option for doctors to treat PTCL patients." Dizal was the first to identify and validate targeting the JAK/STAT pathway as a promising therapeutic approach for PTCL, leading to the development of golidocitinib as the world's first JAK1 only inhibitor. With > 200 to 400-fold selectivity over other JAK family members and ideal pharmacokinetic properties, golidocitinib exerts potent antitumor efficacy with a favorable safety profile. "We are thrilled to bring golidocitinib, the world's first JAK1 only inhibitor, to patients in China, marking the second approved innovative drug from Dizal," said Xiaolin Zhang, PhD, CEO of Dizal. "Golidocitinib yields good antitumor efficacy across different subtypes of PTCL, which differentiate golidocitinib from other targeted therapies. At Dizal, we aspire to discover and develop first-in-class and groundbreaking new medicines to address unmet medical needs around the world. With the US FDA Fast Track designation, we are expediting global development of golidocitinib to bring this exciting drug to patients worldwide." With superior efficacy and safety profile, golidocitinib has been widely acknowledged at prestigious international congresses including ASCO, EHA, ICML, and ASH, with six oral presentations over four consecutive years. The results of the multinational study JACKPOT8 were published in Annals of Oncology and The Lancet Oncology. About golidocitinib (DZD4205) Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, mDoR reached 20.7 months. Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) was published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) was published in The Lancet Oncology (Impact Factor: 54.4). About Dizal Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with two leading assets in global pivotal studies, both of which have already been launched in China. To learn more about Dizal, please visit , or follow us on Linkedin or Twitter. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment, and political, economic, legal, and social conditions. Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect. Contacts Investor Relations: [email protected] Business Development: [email protected] SOURCE Dizal Pharmaceutical

Clinical ResultFast TrackDrug ApprovalASHPriority Review

100 Deals associated with Golidocitinib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peripheral T-Cell Lymphoma	CN	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	18 Jun 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 2	CN	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	01 Jun 2023
T-cell lymphoma recurrent	Phase 2	CN	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	31 May 2022
Cutaneous T-Cell Lymphoma	Phase 2	CN	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	23 Dec 2021
EGFR-mutated non-small Cell Lung Cancer	Phase 2	AU	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	16 Apr 2018
Crohn Disease	Preclinical	CN	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04105010 (JACKPOT8 Part B, Pubmed) Manual	Phase 2	Peripheral T-Cell Lymphoma Second line	104	Golidocitinib 150 mg	agxcvcieqk(hrodamekhv) = neutrophil count decreased (30 [29%]), white blood cell count decreased (27 [26%]), lymphocyte count decreased (22 [21%]), and platelet count decreased (21 [20%]), which were clinically manageable and reversible. Two (2%) due to pneumonia (one case with fungal infection [related to golidocitinib] and another one with COVID-19 infection) and one (1%) due to confusional state. zkthfakmtu (jggxnswozq )	Positive	01 Jan 2024
CTR20213318 (JACKPOT26, ASH2023)	Phase 2	Peripheral T-Cell Lymphoma Maintenance	48	Golidocitinib 150 mg	dlbnfctfei(laottnhuxs) = kzctixjbkn gdxkxpbbgx (gobsmzcjdy ) View more	-	11 Dec 2023
NCT04105010 (JACKPOT8, ASH2023) Manual	Phase 2	Peripheral T-Cell Lymphoma Second line	112	Golidocitinib 150 mg	utrpphvkkg(yyjzmnchpm) = axdmrtzfim pddpdcjpgt (bhwyfqibkh, 33.7 ~ 55.3) View more	Positive	09 Dec 2023
NCT04105010 (JACKPOT8, ICML2023)	Phase 2	Peripheral T-Cell Lymphoma	104	Golidocitinib 150 mg	nzrkrjzkcp(tcjydbqfhn) = qeswugfvjp pibqogxjkn (auinsnefop ) View more	Positive	09 Jun 2023
NCT04105010 (JACKPOT8, ASCO2023) Manual	Phase 2	Peripheral T-Cell Lymphoma	104	Golidocitinib	yphvtkjlkc(kffhsdromp) = kexqpdykxw bntznaioza (onhmvszcbt ) View more	Positive	26 May 2023
NCT04105010 (ASCO2022)	Phase 1/2	Peripheral T-Cell Lymphoma	51	Golidocitinib 150 mg	bbkjacqori(vaacqhaihf) = qqaysapdpf wduhkljwcn (sqzeenmzfm ) View more	-	02 Jun 2022
NCT04105010 (ASCO2022)	Phase 1/2	Peripheral T-Cell Lymphoma	51	Golidocitinib 250 mg	bbkjacqori(vaacqhaihf) = ztnllqyivd wduhkljwcn (sqzeenmzfm ) View more	-	02 Jun 2022
NCT04105010 (EHA2022)	Phase 1/2	Peripheral T-Cell Lymphoma	51	Golidocitinib	dvyoenfslw(lzblpayyct) = ompivyrsmd woonepgzle (qpghtxcpgt ) View more	-	12 May 2022
JACKPOT8 (CSCO2021)	Phase 1/2	Peripheral T-Cell Lymphoma	47	DZD4205 150 mg	jfbaerfepg(ybyfplvlzy) = 41 cases (87.2%) reported at least 1 TEAE during treatment, with 24 cases (51.1%) reporting ≥ CTCAE grade 3 TEAE. 16 cases (34.0%) reported ≥ CTCAE grade 3 TEAE possibly related to DZD4205. The most common (≥10%) ≥ CTCAE grade 3 TEAEs included decreased platelet count (23.4%), decreased neutrophil count (17.0%), and infectious pneumonia (12.8%). The majority of TEAEs were fully recoverable or clinically manageable through dose adjustment. zmpwtnzoay (whhoeteoru )	-	25 Sep 2021
JACKPOT8 (CSCO2021)	Phase 1/2	Peripheral T-Cell Lymphoma	47	DZD4205 250 mg		-	25 Sep 2021
NCT04105010 (JACKPOT8, ICML2021)	Phase 1/2	Peripheral T-Cell Lymphoma	47	DZD4205 150 mg	bnlezqrexy(taytriacqj) = ynmgwqpvaq uxbfvybheo (qtozrapwja ) View more	Positive	17 Jun 2021
NCT04105010 (JACKPOT8, ICML2021)	Phase 1/2	Peripheral T-Cell Lymphoma	47	DZD4205 250 mg	bnlezqrexy(taytriacqj) = bjpmtxtzch uxbfvybheo (qtozrapwja ) View more	Positive	17 Jun 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Golidocitinib

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation